Choosing the Right Dopamine Agonist for Patients with Parkinson's Disease

References

• Calne DB. Treatment of Parkinson’s disease. N Engl J Med 1993;329:1021–7
   PubMed Web of Science ®Google Scholar
• Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson’s disease. Can J Neurol Sci 1992;19:108–12
   PubMed Web of Science ®Google Scholar
• Olanow CW. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson’s disease. In: Olanow CW, Obeso JA (Eds), Dopamine Agonists in Early Parkinson’s Disease. Kent, UK: Wells Medical; 1997:37–52
   Google Scholar
• Piccoli F, Riuggeri RM. Dopaminergic agonists in the treatment of Parkinson’s disease: a review. J Neural Transm 1995;45(Suppl):187–95
   Google Scholar
• Uitti RJ, Ahlskog JE. Comparative review of dopamine receptor agonists in Parkinson’s disease. Drugs 1996;8:369–88
   Google Scholar
• Calne DB, Burton K, Beckman J, Martin WR. Dopamine agonists in Parkinson’s disease. Can J Neurol Sci 1984;11(Suppl 1):221–4
   PubMed Web of Science ®Google Scholar
• Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease (2001): treatment guidelines. Neurology 2001;56(Suppl 5):S1–S88
   PubMed Web of Science ®Google Scholar
• Adler CH, Sethi KD, Hauser RA et al. for the Ropinirole Study Group. Ropinirole for treatment of early Parkinson’s disease. Neurology 1997;49:393–9
   PubMed Web of Science ®Google Scholar
• Shannon KM, Bennett JP, Friedman JH. For the pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997;49:724–8
   PubMed Web of Science ®Google Scholar
• Libman I, Gawel MJ, Riopelle RJ, Bouchard S. A comparison of bromocriptine (Parlodel) and levodopa–carbidopa (Sinemet) for treatment of ‘de novo’ Parkinson’s disease patients. Can J Neurol Sci 1987;14:576–80
   PubMed Web of Science ®Google Scholar
• Barone P, Bravi D, Bermejo-Pareja F et al. and the Pergolide Monotherapy Study Group. Neurology 1999;53:573–9
   PubMed Web of Science ®Google Scholar
• Rondot P, Ziegler M. Activity and acceptability of piribedil in Parkinson’s disease: a multicentre study. J Neurol. 1992;239(Suppl 1):S28–S34
   PubMedGoogle Scholar
• Sweet RD, Wasterlain CG, McDowell FM. Piribedil, a dopamine agonist in Parkinson’s disease. Clin Pharmacol Ther 1974;16:1077–82
   PubMed Web of Science ®Google Scholar
• Truelle JL, Chanelt J, Emile J. Piribedil et Parkinson: étude clinique et électrophysiologique prolongée. Psychol Méd 1979;11(B):207–15
   Google Scholar
• Fahn S, Marsden CD (Eds). Fluctuations of disability in Parkinson’s disease: pathophysiology. In: Movement Disorders, Neurology 2, Butterworth, London, 1982, pp. 123–45
   Google Scholar
• Lees AJ. The ‘on-off’ phenomenon. J Neurol Neurosurg Psych 1989 (Suppl):29–37
   PubMed Web of Science ®Google Scholar
• Poewe WH. Clinical aspects of motor fluctuations in Parkinson’s disease. Neurology 1994;44(Suppl 6):S6–S9
   PubMedGoogle Scholar
• Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson’s disease: a 6-year follow-up study. Neurology 1986;36: 1528–30
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37–45
   PubMed Web of Science ®Google Scholar
• Product labeling information. Physician’s Desk Reference. Montvale, NJ: Medical Economics Company; 2001:668–70
   Google Scholar
• Product labeling information. Physician’s Desk Reference. Montvale, NJ: Medical Economics Company; 2001:2626–30
   Google Scholar
• Product labeling information. Physician’s Desk Reference. Montvale, NJ: Medical Economics Company; 2001:3122–7
   Google Scholar
• Ziegler M. Efficacy of piribedil in adjunction to L-dopa in a 6-month randomized placebo controlled study in early Parkinson’s disease. Neurology April 2000;54(Suppl 3)
   Google Scholar
• Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996;19:234–45
   PubMed Web of Science ®Google Scholar
• Lieberman A, Olanow CW, Sethi K et al. and the Ropinirole Study Group. A multicenter trial of ropinirole as adjunct treatment for Parkinson’s disease. Neurology 1998;51:1057–62
   PubMed Web of Science ®Google Scholar
• Poewe W. Should treatment of Parkinson’s disease be started with a dopamine agonist? Neurology 1998;51(Suppl 2):S21–S24
   PubMed Web of Science ®Google Scholar
• Stocchi F. Dopamine agonists in Parkinson’s disease. What is their role in early treatment? CNS Drugs 1998;10(3):159–70
   Web of Science ®Google Scholar
• Kunkler RB, Osborn DE, Abbott RJ. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson’s disease. Br J Urol 1998;82:147
   PubMedGoogle Scholar
• Lund BC, Neiman RF, Perry PJ. Treatment of Parkinson’s disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Pharmacotherapy 1999;19:1437–8
   PubMed Web of Science ®Google Scholar
• Shaunak S, Wilkins A, Pilling JB, Dick DJ. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide. J Neurol Neurosurg Psych 1999;66:79–81
   PubMed Web of Science ®Google Scholar
• Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf 2000;23:143–64
   PubMed Web of Science ®Google Scholar
• Rajput AH. Adverse effects of ergot-derivative dopamine agonists. In Olanow CW, Obeso JA (Eds), Dopamine Agonists in Early Parkinson’s Disease. Kent, UK:Wells Medical, 1997:209–16
   Google Scholar
• Frucht S, Rogers JD, Greene PE, Gordon MF, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramixerole and ropinirole. Neurology 1999;52:1908–10
   PubMed Web of Science ®Google Scholar
• Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks and Parkinson’s disease treatment. Lancet 2000;355:1332–3
   PubMedGoogle Scholar
• Schapira AH. Sleep attacks (sleep episodes) with pergolide. Lancet 2000;355:1333–4
   PubMedGoogle Scholar
• Olanow CW, Shapira AH, Roth T. Waking up to sleep episodes in Parkinson’s disease. Mov Disord 2000;15:212–5
   PubMed Web of Science ®Google Scholar
• Kryger MH, Roth T, Dement WC (Eds), Principles and Practice of Sleep Medicine, 2nd edn, Philadelphia: WB Saunders; 1994
   Google Scholar
• Schäfer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol 2000;247(Suppl 4):IV/24–IV/27
   Google Scholar
• Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease. A randomized dose-ranging study. JAMA 1997;278:125–30
   Google Scholar
• Ziegler M. Preuves cliniques de l’efficacité du pribédil dans la maladie de Parkinson. Dis Manage Health Out 2001;9 Spec. Issue 1:49–58
   Google Scholar
• Brefel-Courbon C, Rascol O. Stratégies pharmacothérapeutiques actuelles et futures dans la prise en charge de la maladie de Parkinson. Dis Manage Health Out 2001;9 Special Issue 1:31–9
   Google Scholar
• Hubble JP. Pre-clinical studies of pramipexole: clinical relevance. Eur J Neurol 2000;7:15–20
   PubMed Web of Science ®Google Scholar
• Jenner P, Smith LA, Bonhomme C, Chezaubernard C, Jackson M. Piribedil improves vigilance and disability in MPTP treated common marmosets more than L-Dopa. Parkinsonism Rel Dis 2001;7:S59
   Google Scholar
• Malone TJ, Fenwick GM, Pearce VR. Use of piribedil in movement disorder. Age Ageing 1999;28(Suppl 2):169
   PubMedGoogle Scholar
• Shulman LM. How to succed in using dopamine agonists in Parkinson’s disease. Eur J Neurol 2000;7(Suppl 1):9–13
   PubMedGoogle Scholar
• IMS Data View (MAT), October, 2001
   Google Scholar
• Allain H. Propriétés pharmacologiques et pharmacocinétiques du piribedil. Dis Manage Health Out 2001;9(Special Issue 1):41–8
   Google Scholar